Ozempic

GLP-1 drugs like Ozempic and Wegovy, originally framed as obesity treatments for patients with medical need, are increasingly being marketed and used as lifestyle products aimed at customers seeking cosmetic or wellness benefits. Observers note this shift raises questions about how the drugs are prescribed, who accesses them, and how the industry frames their purpose as demand widens beyond clinical obesity care.

An obesity medicine doctor is addressing the growing trend of microdosing Ozempic, the diabetes drug widely used for weight loss, explaining the safety concerns and potential risks of taking lower-than-standard doses. The doctor notes there are limited situations where a low dose may be appropriate, but warns patients against adjusting medication on their own without medical supervision.

A new study finds that people who stop taking GLP-1 weight-loss and diabetes drugs, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings suggest the cardiovascular benefits of these medications depend on continued use, raising questions about how patients should manage long-term treatment.

GLP-1 weight-loss drugs such as Ozempic and Wegovy are being linked to changes in sleep health, with researchers examining how significant weight loss affects sleep apnoea and other sleep disorders. The trend is prompting sleep medicine specialists to rethink diagnosis rates, treatment demand and how therapies like CPAP may be used as more patients take these medications.

A functional medicine expert is cautioning that high doses of GLP-1 weight-loss and diabetes drugs may affect more than appetite, potentially disrupting other bodily processes beyond food cravings. The warning, reported by Fox News, adds to ongoing debate about the safety and long-term effects of medications such as Ozempic and Wegovy as their use continues to expand.